Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
Summary
Third Opinion Trial Synopsis:
This is a study for people with a certain cancer called multiple myeloma. They will use a special test to check for leftover cancer cells after treatment. If there are not many cells left, they will try to avoid a big treatment called AHCT.
This is a study for people with a certain cancer called multiple myeloma. They will use a special test to check for leftover cancer cells after treatment. If there are not many cells left, they will try to avoid a big treatment called AHCT.
*Third Opinion AI Generated Synopsis
Trial Summary
This is a phase II interventional study evaluating the use of minimal residual disease by next generation sequencing to defer autologous hematopoietic stem cell transplantation (AHCT) in patients with newly diagnosed multiple myeloma.
This is a phase II interventional study evaluating the use of minimal residual disease by next generation sequencing to defer autologous hematopoietic stem cell transplantation (AHCT) in patients with newly diagnosed multiple myeloma.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: